Paternal relatives and family history of breast cancer

被引:24
作者
Quillin, John M.
Ramakrishnan, Viswanathan
Borzelleca, Joseph
Bodurtha, Joann
Bowen, Deborah
Wilson, Diane Baer
机构
[1] Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA 23298 USA
[4] Virginia Commonwealth Univ, Div Qual Healthcare, Dept Internal Med, Richmond, VA 23298 USA
[5] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[6] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
关键词
D O I
10.1016/j.amepre.2006.05.002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Reported family medical history may be the most widely accessible genomics screen currently available. The worth of any population-screening tool may be measured by parameters such as sensitivity and specificity. There is some evidence and theory suggesting that family history of breast cancer may be more frequently communicated about maternal (versus paternal) lines. If true, a discrepancy in reporting family history of breast cancer could mean suboptimal accuracy for this genomics-screening tool. Methods: A cross-sectional analysis of reported family history of breast cancer was conducted beginning in early fall 2005 of data collected from April 2003 to March 2005. Study participants were Women's Health Clinic patients without breast cancer aged at least 40 years. The number of women reporting extended paternal relatives (e.g., aunts, grandmothers) with breast cancer was compared to the number of women reporting maternal relatives. Results: More women reported a maternal relative with breast cancer (16%) compared to those reporting paternal relatives (10%) (McNemar odds ratio=1.71, 95% confidence interval=1.26 to 2.34). A discrepancy remained in analyses adjusting for potential covariates (race/ ethnicity, awareness of breast cancer, family communication about breast cancer, and perceived risk). Conclusions: Self-reported family history of breast cancer may not optimally capture inherited risk from the father's side of the family. Further research is needed to look for modifiable contributors to this discrepancy to optimize screening for familial breast cancer.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 35 条
[1]  
ANDERSON DE, 1977, CANCER-AM CANCER SOC, V40, P1855, DOI 10.1002/1097-0142(197710)40:4+<1855::AID-CNCR2820400814>3.0.CO
[2]  
2-1
[3]  
ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO
[4]  
2-J
[5]   Measuring paternal discrepancy and its public health consequences [J].
Bellis, MA ;
Hughes, K ;
Hughes, S ;
Ashton, JR .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2005, 59 (09) :749-754
[6]  
Bowen D, 1997, Womens Health, V3, P227
[7]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[8]   Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women [J].
Canter, JA ;
Kallianpur, AR ;
Parl, FF ;
Millikan, RC .
CANCER RESEARCH, 2005, 65 (17) :8028-8033
[9]  
Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1044
[10]   American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition [J].
Chlebowski, RT ;
Col, N ;
Winer, EP ;
Collyar, DE ;
Cummings, SR ;
Vogel, VG ;
Burstein, HJ ;
Eisen, A ;
Lipkus, I ;
Pfister, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3328-3343